secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001493152-26-013240
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELO shareholders approve acquisition of Teli Pharma and increase share reserve to 11.5M
--------------------------------------------------------------------------------

- Acquisition of Teli Pharmaceuticals approved; issuance of >20% new shares authorized.
- 2023 Omnibus Incentive Plan amended: share reserve increased from 6.5M to 11.5M shares and repricing allowed.
- Bylaws amended to reduce quorum requirement to one-third of outstanding shares.
- Directors elected: Erez Aminov, Matthew Whalen, Edward MacPherson, Matthew Del Giudice.
- Ratification of Salberg & Company as independent auditor for FY 2025 approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226013240/0001493152-26-013240-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226013240/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-013240

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer